The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

To whom it may concern:

February 10, 2021
CompanyTakara Bio Inc.

Headquarters

Nojihigashi 7-4-38, Kusatsu, Shiga 525-0058, Japan

Representative

Koichi Nakao, President & CEOContact

Takuya Kakemi, General Manager of Corporate

Telephone(+81)77-565-6970

Websitehttps://www.takara-bio.co.jp/(First Section of the TSE, code: 4974)

Management Division, Executive Officer

Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
Kusatsu/Shiga, Japan-February 10, 2021 – Takara Bio Inc. (Takara Bio), announced the revision of the consolidated

financial forecast and the dividend forecast for the fiscal year ending March 31, 2021 (April 1, 2020 – March31, 2021) that was disclosed on November 10, 2020, as follows based on a review of current trends in resultsof operations.
1. Revision to Financial Forecast(1) Revision to the Consolidated Forecast for the fiscal year ending March 31, 2021(April 1, 2020 – March 31, 2021)
Operating profit

Ordinary profit

Net income
attributable toowners of parent

Net income pershareMillion yen

Million yen

Million yen

Million yen

Yen

40,800

8,000

8,100

5,000

41.52

Revised forecast (B)45,20012,00012,100

7,800

64.78

Amount of Change (B-A)

4,400

4,000

4,000

2,800

－

Percentage of change (%)(Reference) Results forthe previous fiscal year
ended March 31, 2020

10.8

50.0

49.4

56.0

－

34,565

6,274

6,347

3,819

31.72

Net sales

Previous forecast (A)(2) Reason of the Revision

As for the consolidated forecasts, the Company has revised the financial forecast disclosed on
November 10, 2020, considering results for the nine months ended December 31, 2020 and recent
progress in its business.
Despite the impact of the new coronavirus disease pandemic, net sales of research reagents andscientific instruments are expected to be steady, exceeding the previous forecast. In addition, demand
for new coronavirus testing-related products, such as in vitro diagnostics, is expected to continue toincrease.
With regard to profits, gross profit is expected to significantly exceed the previous forecast due to anincrease in net sales, as well as a further decline in the cost of sales ratio due to changes in the salescomposition and an improvement in the production utilization rate, etc. Although selling, general andadministrative expenses will increase mainly due to R&D expenses, each profit item is expected toexceed the previous forecast and hit a record high, and operating profit and ordinary profit are expected
to increase for the 12th consecutive fiscal year.
For the reasons stated above, net sales, operating profit, ordinary profit, and net income

attributable to owners of the parent are each expected to exceed the previous forecasts,
and therefore the forecasts for the full fiscal year have been revised.
2. Revision to Dividend Forecast(1) Details of Revised Dividend Forecast
Dividend per share (Yen)Record datend

End of 2 quarter

Previous forecast

End of fiscal year

Total

9.00

9.00

14.00

14.00

8.00

8.00

(Disclosed on November 10, 2020)
Revised forecast
Actual amount for the current fiscal year
Actual amount for the previous fiscal
year (fiscal year ended March 31, 2020)

0.00
0.00

(2) Reason of the Revision
Considering the management performance and financial statement comprehensively, Takara Bio
recognizes a basic policy aimed for profit contribution, positioning an important business
management issue to distribute profits to shareholders as well as enhancing the internal reserves tostrengthen the research development activities in Bioindustry and Gene Therapy businesses.
Specifically, the dividends of surplus will be paid at around 20% of estimated profit calculated
without considering extraordinary income or loss in the consolidated financial statements.
Takara Bio decided to upwardly revise the forecasted year-end dividend for fiscal 2021 by of ¥5.00
per share from ¥9.00 to ¥14.00 under the revision of financial forecast and the shareholder return
policy shown above.
As for the year-end dividend for fiscal 2021, it will be resolved at the 19 th Annual General Meetingof Shareholders held in June 2021.

Forward-Looking Statements
Statements contained in these materials with respect to the Company's current plans, forecasts, strategies andbeliefs that are not historical facts are forward-looking statements about the future performance of the Company
and its consolidated subsidiaries. These statements are based on management's assumptions and beliefs in lightof information currently available to it, but are based on a number of assumptions and beliefs derived frominformation that contains significant risks and uncertainties. Actual results may differ materially from these
forecasts due to various factors. Factors that could influence actual results include, but are not limited to,
economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes inlaws and government systems, pressure from competitors' prices and product strategies, declines in selling
power of the Company's existing and new products, disruptions to production, violations of our intellectual
property rights, rapid advances in technology, and unfavorable verdicts in major litigation.